Pallas Health vs Embody: clinician choice or low-cost semaglutide
Pallas Health vs Embody is a choice between clinician-selected brand or compounded GLP-1s and a low-cost, fast-delivery compounded-only option. Early verdict: choose Pallas Health if you want access to FDA-approved brand-name GLP-1s plus compounded options reviewed by a US-licensed clinician; choose Embody if the main priority is the lowest advertised monthly price and fast 1-2 day shipping after approval.
Pallas Health vs Embody: 5 key differences to compare
This direct comparison focuses on the most distinctive supported differences: medication types offered, pricing structure, shipping and delivery, clinician and care features, and regulatory notes. Each point compares both providers side by side using only supplied facts.
1. Medication options and scope
Pallas Health offers FDA-approved Wegovy, Ozempic, Zepbound and Mounjaro, plus clinician-personalized compounded semaglutide and tirzepatide prepared in the USA when a brand medication is not the right fit. Embody offers compounded semaglutide and tirzepatide only, without branded Ozempic, Wegovy, or Zepbound.
See Embody pricing and options
2. Pricing model and sample costs
Pallas Health lists compounded semaglutide at $139 for the first month, then $597 every 12 weeks (a $199/month average). Compounded tirzepatide is $179 first month, then $897 every 12 weeks ($299/month average). Pallas also lists cash-pay brand prices for Wegovy, Ozempic, Zepbound and Mounjaro. Embody advertises compounded semaglutide at $69/month (cut from $299) and compounded tirzepatide at $119/month, with flat locked-in monthly pricing; Embody states final pricing may vary by dose and clinician recommendation.
3. Shipping and delivery promises
Pallas Health offers free expedited and discreet shipping on every plan and says compounded medications are prepared by US-licensed compounding pharmacies. Embody promises free shipping with fast 1–2 day delivery after approval.
4. Clinician review, care and platform features
Pallas Health emphasizes a US-licensed clinician who reviews health history and personalizes whether a brand-name pen or a compounded preparation is right, with provider care, ongoing check-ins and care-team messaging included in one all-in plan price and no membership fee. Pallas is 100% online and asynchronous in most states, though a video visit is required in seven states plus Washington, D.C. Embody provides a licensed provider review handled online, prescription and telemed visits included, with no long-term commitment and cancel anytime; Embody notes 24/7 support access for dosing and side-effect questions.
5. Regulatory and product notes
Both providers supply compounded medications; each includes the regulatory qualifier that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Pallas states it does not manufacture or compound medication and that compounded meds are prepared by US-licensed compounding pharmacies; the medication may differ in appearance from products shown. Embody similarly notes its compounded medications are not FDA-approved finished products but use the same active ingredients as brand GLP-1s.
Comparison table: Pallas Health vs Embody
| Criteria | Pallas Health | Embody |
|---|---|---|
| Medication types | FDA-approved brand-name GLP-1s and compounded semaglutide/tirzepatide | Compounded semaglutide and tirzepatide only |
| Starter price example | Compounded semaglutide $139 first month, then $199/mo avg | Compounded semaglutide $69/month (advertised) |
| Pricing model | Intro month then 12-week renewals for compounded plans; brand cash-pay monthly pricing listed | Flat locked-in monthly pricing; final pricing may vary by dose |
| Shipping | Free expedited discreet shipping | Free shipping, arrives in 1–2 days after approval |
| Clinician and care | US-licensed clinician review, care/team messaging and check-ins included, asynchronous in most states | Licensed provider review online, telemed included, 24/7 support access |
| Regulatory note | Compounded meds are not FDA-approved | Compounded meds are not FDA-approved |
How these differences affect your choice
If access to brand-name, FDA-approved GLP-1s under clinician guidance matters, Pallas Health is explicitly positioned to let a US-licensed clinician select between brand pens and compounded preparations and includes provider care in the plan price. If lowest advertised monthly cost and fastest shipping after approval are the priority, Embody advertises $69/month semaglutide and free 1–2 day delivery.
Pallas Health vs Embody: final guidance
Choose Pallas Health if you want a clinician to choose between FDA-approved brand-name GLP-1s and a per-patient compounded preparation, with provider care and messaging included in one plan price. Choose Embody if you want the lowest advertised compounded semaglutide monthly price and fast 1–2 day shipping after approval, accepting that it offers compounded medication only and fewer premium features.